Skip to main content
Official Website of Stem Cell Mexico – Since 2002
Stem Cell Therapy Mexico

How effective is stem cell therapy for congestive heart failure?

Stem cell therapy for congestive heart failure (CHF) has shown encouraging but mixed evidence of effectiveness. Some randomized trials report improvements in heart function, symptoms or quality of life, while others, including the largest trial to date, did not meet their main goal.

Free Consultation
Heart location on a neutral human figure

A Cochrane review found that cell therapy was associated with lower long-term mortality, with variable effects on heart pumping function. One small randomized trial using intravenous (IV) umbilical cord mesenchymal stem cells (MSCs), the RIMECARD trial, reported a greater increase in ejection fraction and better functional class at 12 months compared with placebo. At Stem Cell Mexico, CHF protocols use only allogeneic MSCs from Wharton's jelly of the umbilical cord, given by IV infusion, as a complement to guideline-based heart failure care. Results vary between individuals.

This guide explains how effectiveness is measured in heart failure, what the main studies show, which factors influence results and how to set realistic expectations.

Heart failure in brief

Heart failure means the heart cannot pump or fill with enough blood to meet the body's needs. It is commonly classified by ejection fraction (EF), the percentage of blood the left ventricle pumps out with each beat:

  • Heart failure with reduced ejection fraction (HFrEF): EF of 40% or less, often after heart attacks or due to cardiomyopathy.
  • Heart failure with mildly reduced ejection fraction (HFmrEF): EF between 41% and 49%.
  • Heart failure with preserved ejection fraction (HFpEF): EF of 50% or more, with stiff heart muscle that fills poorly, often related to high blood pressure, diabetes, obesity and aging.

Symptoms include shortness of breath, fatigue, swelling in the legs and reduced exercise capacity. Severity is often described with the New York Heart Association (NYHA) classes I to IV.

How effectiveness is measured

In heart failure research, "effective" can mean different things:

  • Hard outcomes: survival, hospitalizations for heart failure, heart attacks and strokes.
  • Heart function: ejection fraction, heart size and filling pressures, measured by echocardiography or cardiac MRI.
  • Biomarkers: blood levels of NT-proBNP, which reflect strain on the heart.
  • Functional capacity: six-minute walk distance, exercise testing and NYHA class.
  • Quality of life: standardized questionnaires such as the Minnesota Living with Heart Failure Questionnaire or the Kansas City Cardiomyopathy Questionnaire.

A treatment can improve one of these measures without changing others. Regulators and cardiologists give the most weight to hard outcomes, because they reflect what matters most to patients over time.

What the evidence shows

Cochrane systematic review

A Cochrane review of 38 randomized trials with about 1,900 participants, most using bone-marrow-derived cells in chronic ischemic heart disease and heart failure, found that cell therapy was associated with lower long-term mortality and fewer non-fatal heart attacks and arrhythmias. It did not show a consistent improvement in heart function on MRI or a reduction in heart failure hospitalizations.

DREAM-HF

The phase 3 DREAM-HF trial, published in the Journal of the American College of Cardiology, studied allogeneic mesenchymal precursor cells injected directly into the heart muscle through a catheter in 565 patients with chronic HFrEF. The cells did not reduce the primary endpoint of recurrent heart failure hospitalizations. Secondary analyses suggested fewer heart attacks and strokes and possible benefit in patients with more inflammation. These findings are guiding new studies. Direct injection into the heart is a different and more invasive route than IV infusion.

RIMECARD: IV umbilical cord MSCs

The RIMECARD trial, published in Circulation Research, randomized 30 patients with stable HFrEF to IV umbilical cord MSCs or placebo. At 12 months, ejection fraction improved by about 7 percentage points in the treated group compared with about 2 points in the placebo group, with better NYHA class and quality of life scores. No differences were seen in mortality, hospitalizations, arrhythmias or cancer.

Safety

Meta-analyses of controlled trials of IV MSCs, including a 2026 analysis focused on umbilical-cord-derived cells, show temporary fever as the most consistent side effect, without an increase in serious infection, thrombosis, cancer or death. This supports continued research, but no treatment is free of risk, and people with heart failure need careful management of fluids and blood pressure during any infusion.

Regulatory context

No stem cell therapy is approved by the FDA or the European Medicines Agency for heart failure. The European Society of Cardiology heart failure guidelines base treatment on medications, devices and lifestyle measures with strong evidence, and do not include cell therapy as a standard treatment.

How MSCs are thought to work in heart failure

MSCs from Wharton's jelly do not become new heart muscle in meaningful amounts. Their proposed effects are paracrine: releasing factors that may reduce inflammation, limit scarring (fibrosis), support the formation of small blood vessels and improve the function of the heart's own cells. Chronic inflammation is increasingly recognized as a contributor to heart failure progression, which is one reason researchers are interested in the anti-inflammatory profile of MSCs. After IV infusion, many cells are temporarily trapped in the lungs, and effects are believed to come from systemic signaling rather than from cells settling in the heart.

Factors that influence results

  • Type and cause of heart failure: ischemic and non-ischemic HFrEF, and HFpEF, have different biology. Most trials have studied HFrEF.
  • Severity: people with very advanced disease (NYHA IV, frequent hospitalizations) have the least reserve and the highest risk.
  • Optimized standard therapy: results are best interpreted when patients already take guideline-recommended medications at appropriate doses.
  • Inflammation: some data suggest patients with higher inflammatory markers may respond differently.
  • Comorbidities: kidney disease, diabetes, lung disease and arrhythmias affect outcomes.
  • Lifestyle: salt and fluid management, physical activity, weight, alcohol and smoking all matter.

Standard care comes first

According to the ESC guidelines, the foundation of HFrEF treatment includes four classes of medications: ACE inhibitors or ARNI, beta blockers, mineralocorticoid receptor antagonists and SGLT2 inhibitors, along with diuretics for congestion. Devices such as implantable defibrillators and cardiac resynchronization therapy help selected patients. Cardiac rehabilitation, vaccination and management of other conditions are also important. These treatments have been shown in large trials to improve survival and reduce hospitalizations. Cell therapy, when considered, should be added to this foundation, never replace it.

How treatment is done at Stem Cell Mexico

  • Cells: allogeneic MSCs from Wharton's jelly of donated umbilical cords, obtained after healthy, full-term births with informed consent and donor screening. No autologous cells or other cell sources are used.
  • Laboratory: cells are produced in a COFEPRIS-licensed laboratory under Good Manufacturing Practice standards, with quality and safety testing before release.
  • Evaluation: we request a recent echocardiogram, ECG, blood tests including kidney function and NT-proBNP when available, and a report from your cardiologist.
  • Infusion: slow IV infusion with monitoring of blood pressure, heart rate, oxygen and fluid status, followed by observation.
  • Follow-up: we recommend repeating the same tests at defined intervals, ideally with your cardiologist, to measure change objectively.

Realistic expectations

Some patients report better energy, breathing or exercise tolerance in the months after treatment, and some show improvements in echocardiographic measures. Others notice no meaningful change. Because heart failure symptoms also fluctuate with medication changes, fluid status and season, objective tests before and after treatment are the best way to judge results.

Warning signs when comparing clinics

Be cautious if a clinic:

  • Promises to reverse heart failure or replace medications.
  • Uses satisfaction rates or testimonials instead of objective test results.
  • Says the treatment is risk-free.
  • Does not request your echocardiogram, labs and cardiology reports.
  • Cannot explain the cell source, dose, route and laboratory testing.

Who may be a candidate

  • Stable chronic heart failure, on optimized medical therapy for at least several months.
  • No recent heart attack, unstable angina or decompensated heart failure.
  • No active infection and no cancer within the past five years.
  • Continued follow-up with a cardiologist.

What our patients usually receive

Based on the treatment plans our team prepares for patients, a typical protocol at Stem Cell Mexico includes:

  • Wharton's jelly MSCs by IV infusion, usually between 100 and 200 million cells, depending on the condition, body weight and medical review.
  • One night at our facilities, sometimes two, with nursing and medical monitoring.
  • Consultation with your doctor and the stem cell specialist, pre-treatment laboratory tests and ground transportation from the San Diego airport area.
  • Complementary therapies, such as PRP, exosomes or NAD+, only when the doctor considers them useful; they are always listed in your written plan.

Recovery is gradual, and each person responds differently. Some patients begin noticing changes within the first weeks, while others notice them over the following months, which is why our team stays in contact after treatment to follow your progress and decide whether a second application could help.

Questions to ask during your evaluation

  • Is my current medication plan fully optimized?
  • What improvements are realistic in my type and stage of heart failure?
  • Which tests will be used to measure change, and when?
  • How will fluids and blood pressure be managed during the infusion?
  • What are the possible risks in my situation?

Bottom line

The effectiveness of stem cell therapy for congestive heart failure varies between patients. Some trials, including a small randomized study of IV umbilical cord MSCs, report improvements in heart function and quality of life, while the largest trial did not meet its main goal. At Stem Cell Mexico, treatment with Wharton's jelly MSCs is offered as a complement to guideline-based cardiology care, with results that vary between individuals. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your heart condition, goals and medical history.

References

  1. Cochrane: Fisher SA et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure, 2016 (opens in a new tab)
  2. Perin EC et al. Randomized trial of targeted transendocardial mesenchymal precursor cell therapy in patients with heart failure (DREAM-HF). Journal of the American College of Cardiology, 2023 (opens in a new tab)
  3. Bartolucci J et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial). Circulation Research, 2017 (opens in a new tab)
  4. European Society of Cardiology (ESC): 2021 Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal (opens in a new tab)
  5. Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)

Request your medical evaluation

A clearer path starts here.

Tell us a little about yourself. We’ll help you understand the next step.

Vania, patient coordinator at Stem Cell Mexico

Vania, our patient coordinator

Your questions. Your travel plans.
A real person to help.

Talk to Vania on WhatsApp (opens in a new tab)

What happens next?

  1. Your advisor contacts you.
  2. We explain the medical review.
  3. You explore your options.

Call +1 800 646 0290

Let’s begin with you.

Your inquiry starts a conversation. Treatment requires medical evaluation.

Vania · Patient Advisor

Start my free evaluation
Free Consultation